NeuroVive gets $4 million for genetic mitochondrial diseases program

29 August 2018

Shares of Swedish mitochondrial medicine firm NeuroVive Pharmaceutical (Nasdaq OMX: NVP) gained 2.3% to 4.21 Swedish kronor after it announced new funding from the USA.

Scientists at the company’s research partner the Children’s Hospital of Philadelphia (CHOP) have received a three-year grant (W81XWH-17-PRMRP-TTDA), in total of just over $4 million from the US Department of Defense, Office of the Congressionally Directed Medical Research Programs (CDMRP) for studies focused on NeuroVive’s NVP015 program for genetic mitochondrial diseases.

The extensive program evaluating preclinical efficacy and exploring viable future clinical endpoints for the NVP015 program, will be conducted by a team of world leading experts under the leadership of principal investigator Dr Todd Kilbaugh, Associate Professor of Anesthesiology, Critical Care and Pediatrics. The objective of the therapeutic development program is to develop a drug candidate for Investigational New Drug (IND) submission to the Food and Drug Administration (FDA) for initiation of Phase I clinical trials.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK